Anonymous
Guest
Anonymous
Guest
In an immediate and specific fashion, the Merck announcement revealed a level of deceit on the part of Merck management that has become all too common in pharma during recent years. Someone at the press conference asked CEO Ken Frazier if the current cuts to R&D spending and staff mean he is abandoning his 2011 position where he said Merck will pursue a different strategy than Pfizer and other Big Pharmas that decided at the time to cut their research budgets (see here).
Frazier professed to see no change or contradiction. Instead he said his 2011 statement didn't suggest Merck wouldn't cut R&D, just that they wouldn't make "indiscriminate" cuts to prop up short-term earnings (see here).
Read more at http://www.philly.com/philly/blogs/...fundamental-problems.html#86KDBqwk2tGoPwcQ.99
http://www.philly.com/philly/blogs/healthcare/Merck-layoffs-reveal-fundamental-problems.html
Frazier professed to see no change or contradiction. Instead he said his 2011 statement didn't suggest Merck wouldn't cut R&D, just that they wouldn't make "indiscriminate" cuts to prop up short-term earnings (see here).
Read more at http://www.philly.com/philly/blogs/...fundamental-problems.html#86KDBqwk2tGoPwcQ.99
http://www.philly.com/philly/blogs/healthcare/Merck-layoffs-reveal-fundamental-problems.html